Cargando…

Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin

BACKGROUND: Oral semaglutide was approved in 2019 for blood glucose control in patients with type 2 diabetes mellitus (T2DM) and was the first oral glucagon-like peptide 1 receptor agonist (GLP-1 RA). T2DM is associated with substantial healthcare expenditures in the US, so the cost of a new interve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wehler, Elizabeth, Lautsch, Dominik, Kowal, Stacey, Davies, Glenn, Briggs, Andrew, Li, Qianyi, Rajpathak, Swapnil, Alsumali, Adnan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882575/ https://www.ncbi.nlm.nih.gov/pubmed/33150566 http://dx.doi.org/10.1007/s40273-020-00967-7

Ejemplares similares

Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis
por: Lautsch, Dominik, et al.
Publicado: (2020)

Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event
por: Alsumali, Adnan, et al.
Publicado: (2021)

SAT-139 Clinical Impact of Oral Semaglutide Compared with Sitagliptin in T2D on Metformin ± Sulfonylurea: The Pioneer 3 Trial
por: Rosenstock, Julio, et al.
Publicado: (2019)

Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
por: Lautsch, Dominik, et al.
Publicado: (2019)

Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
por: Alsumali, Adnan, et al.
Publicado: (2021)

The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
por: Ehlers, Lars H., et al.
Publicado: (2022)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
por: Degli Esposti, Luca, et al.
Publicado: (2014)

A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
por: Wehler, Elizabeth, et al.
Publicado: (2019)

Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
por: Wehler, Elizabeth, et al.
Publicado: (2019)

Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial
por: Chawla, Shalini, et al.
Publicado: (2013)

Spectroflourometric and Spectrophotometric Methods for the Determination of Sitagliptin in Binary Mixture with Metformin and Ternary Mixture with Metformin and Sitagliptin Alkaline Degradation Product
por: El-Bagary, Ramzia I., et al.
Publicado: (2011)

Negative global phosphorus budgets challenge sustainable intensification of grasslands
por: Sattari, S. Z., et al.
Publicado: (2016)

Multiple uncontrolled conditions and blood pressure medication intensification: an observational study
por: Salanitro, Amanda H, et al.
Publicado: (2010)

Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy
por: Inzucchi, S. E., et al.
Publicado: (2015)

Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
por: Patel, Tirath, et al.
Publicado: (2023)

Improved Chromatographic Separation of Sitagliptin Phosphate and Metformin Hydrochloride
por: Hendy, Moataz S.
Publicado: (2015)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Addressing Therapeutic Inertia: Development and Implementation of an Electronic Health Record–Based Diabetes Intensification Tool
por: Pantalone, Kevin M., et al.
Publicado: (2023)

Metformin adherence and discontinuation among patients with type 2 diabetes: A retrospective cohort study
por: Tang, Yuexin, et al.
Publicado: (2020)

Medication use by US patients with pulmonary hypertension associated with chronic obstructive pulmonary disease: a retrospective study of administrative data
por: Weiss, Tracey J., et al.
Publicado: (2022)

Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
por: Hausner, Helene, et al.
Publicado: (2017)

Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
por: Eliasson, Björn, et al.
Publicado: (2022)

Individualized HbA(1c) Goals, and Patient Awareness and Attainment of Goals in Type 2 Diabetes Mellitus: A Real-World Multinational Survey
por: Lautsch, Dominik, et al.
Publicado: (2021)

New combination treatments in the management of diabetes: focus on sitagliptin – metformin
por: Green, Jennifer, et al.
Publicado: (2008)

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study
por: Ahmed, Ibrar, et al.
Publicado: (2022)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects
por: Bækdal, Tine A., et al.
Publicado: (2019)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Reynolds, Jonathan K
Publicado: (2009)

Papulonodular Lesions in a Patient of Diabetes Mellitus Receiving Sitagliptin and Metformin
por: Agrawal, Prabhat, et al.
Publicado: (2021)

Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
por: Buse, John B, et al.
Publicado: (2020)

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
por: Bain, Stephen C., et al.
Publicado: (2019)

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
por: Philis-Tsimikas, A, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30‐week, double‐blind, phase 3a, randomized trial
por: Ji, Linong, et al.
Publicado: (2021)

Dose distribution and up‐titration patterns of metformin monotherapy in patients with type 2 diabetes
por: Iglay, Kristy, et al.
Publicado: (2019)

Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes
por: Ji, Ming, et al.
Publicado: (2016)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Barnard, Karen, et al.
Publicado: (2010)

Clinical utility and patient considerations in the use of the sitagliptin–metformin combination in Chinese patients
por: Du, Qiang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7elnanm072r5mr4urj7prqghvd